The EIB has worked with Israel since 1981. We have supported the construction of a seawater desalination plant that increased the availability of this precious resource in a water-scarce region and enhanced the quality of water delivered to local homes. Through “Innovfin Infectious Diseases”, part of the Horizon 2020 programme, we support Israel’s smart investments in basic research, an important catalyst for establishing globally leading industries in Europe.
Another equity investment was made by the European Investment Fund (EIF), part of the EIB Group, in the ICV III fund to support seed and early stage companies promoting new technologies and business models.
At a glance
The EIB provides finance and expertise for sound and sustainable investment projects in Israel.
The European Investment Bank (EIB) and BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV), developer of the Universal Flu Vaccine candidate M-001, announced that they have entered into a €20 million (approximately $22 million) loan agreement.